- Patients
- Clinical Research
- Clinical trials
- CODEBREAK-202
2024-02-12T00:00:00.000+00:00
Ongoing
CODEBREAK-202
CODEBREAK-202
Lung cancer
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12Cersus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Patients with Stage IV and Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Positive for KRAS G12C
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12Cersus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Patients with Stage IV and Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Positive for KRAS G12C
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Lung
Study Phase
III |
Trial Identifiers
Registration number: NCT05920356. https://clinicaltrials.gov/study/NCT05920356
|
GenesisCare Location(s)
GenesisCare North Shore
GenesisCare North Shore
:::
Principal Investigator(s)